<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns="http://purl.org/rss/1.0/">
<channel rdf:about="http://www.nature.com/ncpendmet/current_issue/rss">
<title>Nature Clinical Practice Endocrinology &amp; Metabolism</title>
<description>Nature Clinical Practice Endocrinology &amp; Metabolism provides physicians with authoritative and timely interpretations of key developments in the field, translating the latest findings into clinical practice.</description>
<link>http://www.nature.com/ncpendmet/current_issue/</link>
<dc:publisher>Nature Publishing Group</dc:publisher>
<dc:language>en</dc:language>
<dc:rights>&#169; 2008 Nature Publishing Group</dc:rights>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:issn>1745-8366</prism:issn>
<prism:eIssn>1745-8374</prism:eIssn>
<prism:copyright>&#169; 2008 Nature Publishing Group</prism:copyright>
<prism:rightsAgent>permissions@nature.com</prism:rightsAgent>
<image rdf:resource="http://www.nature.com/includes/rj_globnavimages/ncpendmet_logo.gif"/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0871"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0847"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0848"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0849"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0850"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0851"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0852"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0853"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0854"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0855"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0856"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0857"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0858"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0859"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0860"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0835"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0836"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0841"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0838"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0840"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0845"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0839"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0842"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0843"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0846"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0872"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0844"/>
<rdf:li rdf:resource="http://dx.doi.org/10.1038/ncpendmet0888"/>
</rdf:Seq>
</items>
</channel>
<image rdf:about="http://www.nature.com/includes/rj_globnavimages/ncpendmet_logo.gif">
<title>Nature Clinical Practice Endocrinology &amp; Metabolism</title>
<url>http://www.nature.com/includes/rj_globnavimages/ncpendmet_logo.gif</url>
<link>http://www.nature.com/ncpendmet/</link>
</image>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0871">
<title>Dr Joseph Edward Rall</title>
<link>http://dx.doi.org/10.1038/ncpendmet0871</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Dr Joseph Edward Rall</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 359 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0871">doi:10.1038/ncpendmet0871</a>
</p>
<p>Authors: Jan Wolff
&amp; P Reed Larsen</p>
]]></content:encoded>
<dc:title>Dr Joseph Edward Rall</dc:title>
<dc:creator>Jan Wolff</dc:creator>
<dc:creator>P Reed Larsen</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0871</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 359 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Editorial</prism:section>
<prism:startingPage>359</prism:startingPage>
<prism:endingPage>359</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0847">
<title>A TNFRS11B mutation is associated with BMD and risk of hip fracture</title>
<link>http://dx.doi.org/10.1038/ncpendmet0847</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>A TNFRS11B mutation is associated with BMD and risk of hip fracture</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 360 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0847">doi:10.1038/ncpendmet0847</a>
</p>
]]></content:encoded>
<dc:title>A TNFRS11B mutation is associated with BMD and risk of hip fracture</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0847</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 360 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>360</prism:startingPage>
<prism:endingPage>360</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0848">
<title>Low testosterone levels are associated with insulin resistance in men with diabetes</title>
<link>http://dx.doi.org/10.1038/ncpendmet0848</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Low testosterone levels are associated with insulin resistance in men with diabetes</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 360 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0848">doi:10.1038/ncpendmet0848</a>
</p>
]]></content:encoded>
<dc:title>Low testosterone levels are associated with insulin resistance in men with diabetes</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0848</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 360 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>360</prism:startingPage>
<prism:endingPage>360</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0849">
<title>Elevated sex-hormone-binding globulin level is an independent risk factor for hip fracture</title>
<link>http://dx.doi.org/10.1038/ncpendmet0849</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Elevated sex-hormone-binding globulin level is an independent risk factor for hip fracture</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 360 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0849">doi:10.1038/ncpendmet0849</a>
</p>
]]></content:encoded>
<dc:title>Elevated sex-hormone-binding globulin level is an independent risk factor for hip fracture</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0849</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 360 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>360</prism:startingPage>
<prism:endingPage>361</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0850">
<title>Results of testosterone-doping test depend on UGT2B17 genotype</title>
<link>http://dx.doi.org/10.1038/ncpendmet0850</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Results of testosterone-doping test depend on UGT2B17 genotype</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 361 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0850">doi:10.1038/ncpendmet0850</a>
</p>
]]></content:encoded>
<dc:title>Results of testosterone-doping test depend on UGT2B17 genotype</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0850</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 361 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>361</prism:startingPage>
<prism:endingPage>361</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0851">
<title>Health risks and benefits change after withdrawal of estrogen plus progestin therapy</title>
<link>http://dx.doi.org/10.1038/ncpendmet0851</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Health risks and benefits change after withdrawal of estrogen plus progestin therapy</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 361 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0851">doi:10.1038/ncpendmet0851</a>
</p>
]]></content:encoded>
<dc:title>Health risks and benefits change after withdrawal of estrogen plus progestin therapy</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0851</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 361 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>361</prism:startingPage>
<prism:endingPage>362</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0852">
<title>Genotype influences lipid profile and incident cardiovascular disease risk</title>
<link>http://dx.doi.org/10.1038/ncpendmet0852</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Genotype influences lipid profile and incident cardiovascular disease risk</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 362 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0852">doi:10.1038/ncpendmet0852</a>
</p>
]]></content:encoded>
<dc:title>Genotype influences lipid profile and incident cardiovascular disease risk</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0852</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 362 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>362</prism:startingPage>
<prism:endingPage>362</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0853">
<title>Growth-hormone therapy might not improve exercise capacity</title>
<link>http://dx.doi.org/10.1038/ncpendmet0853</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Growth-hormone therapy might not improve exercise capacity</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 362 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0853">doi:10.1038/ncpendmet0853</a>
</p>
]]></content:encoded>
<dc:title>Growth-hormone therapy might not improve exercise capacity</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0853</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 362 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>362</prism:startingPage>
<prism:endingPage>362</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0854">
<title>CTGF might have a role in vascular and renal disease associated with type 1 diabetes</title>
<link>http://dx.doi.org/10.1038/ncpendmet0854</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>CTGF might have a role in vascular and renal disease associated with type 1 diabetes</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 363 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0854">doi:10.1038/ncpendmet0854</a>
</p>
]]></content:encoded>
<dc:title>CTGF might have a role in vascular and renal disease associated with type 1 diabetes</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0854</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 363 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>363</prism:startingPage>
<prism:endingPage>363</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0855">
<title>Lipid-lowering therapy could protect against peripheral neuropathy</title>
<link>http://dx.doi.org/10.1038/ncpendmet0855</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Lipid-lowering therapy could protect against peripheral neuropathy</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 363 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0855">doi:10.1038/ncpendmet0855</a>
</p>
]]></content:encoded>
<dc:title>Lipid-lowering therapy could protect against peripheral neuropathy</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0855</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 363 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>363</prism:startingPage>
<prism:endingPage>363</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0856">
<title>Metformin benefits low-birth-weight girls with precocious pubarche</title>
<link>http://dx.doi.org/10.1038/ncpendmet0856</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Metformin benefits low-birth-weight girls with precocious pubarche</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 363 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0856">doi:10.1038/ncpendmet0856</a>
</p>
]]></content:encoded>
<dc:title>Metformin benefits low-birth-weight girls with precocious pubarche</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0856</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 363 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>363</prism:startingPage>
<prism:endingPage>364</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0857">
<title>Daily rhPTH1&#8211;84 injections could be avoided in osteoporosis treatment</title>
<link>http://dx.doi.org/10.1038/ncpendmet0857</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Daily rhPTH1&#8211;84 injections could be avoided in osteoporosis treatment</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 364 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0857">doi:10.1038/ncpendmet0857</a>
</p>
]]></content:encoded>
<dc:title>Daily rhPTH1&#8211;84 injections could be avoided in osteoporosis treatment</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0857</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 364 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>364</prism:startingPage>
<prism:endingPage>364</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0858">
<title>Pioglitazone treatment decreases BMD even in estrogen-replete women</title>
<link>http://dx.doi.org/10.1038/ncpendmet0858</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Pioglitazone treatment decreases BMD even in estrogen-replete women</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 364 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0858">doi:10.1038/ncpendmet0858</a>
</p>
]]></content:encoded>
<dc:title>Pioglitazone treatment decreases BMD even in estrogen-replete women</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0858</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 364 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>364</prism:startingPage>
<prism:endingPage>365</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0859">
<title>Identification of a serum biomarker profile that could aid early diagnosis of osteoporosis</title>
<link>http://dx.doi.org/10.1038/ncpendmet0859</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Identification of a serum biomarker profile that could aid early diagnosis of osteoporosis</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 365 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0859">doi:10.1038/ncpendmet0859</a>
</p>
]]></content:encoded>
<dc:title>Identification of a serum biomarker profile that could aid early diagnosis of osteoporosis</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0859</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 365 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>365</prism:startingPage>
<prism:endingPage>365</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0860">
<title>Patients with MEN1-associated ZES have a severe form of hyperparathyroidism</title>
<link>http://dx.doi.org/10.1038/ncpendmet0860</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Patients with MEN1-associated ZES have a severe form of hyperparathyroidism</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 365 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0860">doi:10.1038/ncpendmet0860</a>
</p>
]]></content:encoded>
<dc:title>Patients with MEN1-associated ZES have a severe form of hyperparathyroidism</dc:title>
<dc:identifier>doi:10.1038/ncpendmet0860</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 365 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Research Highlights</prism:section>
<prism:startingPage>365</prism:startingPage>
<prism:endingPage>365</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0835">
<title>Can serum pentosidine levels predict risk of vertebral fracture in patients with type 2 diabetes mellitus?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0835</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Can serum pentosidine levels predict risk of vertebral fracture in patients with type 2 diabetes mellitus?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 366 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0835">doi:10.1038/ncpendmet0835</a>
</p>
<p>Author: Karl Insogna</p>
]]></content:encoded>
<dc:title>Can serum pentosidine levels predict risk of vertebral fracture in patients with type 2 diabetes mellitus?</dc:title>
<dc:creator>Karl Insogna</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0835</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 366 (2008)</dc:source>
<dc:date>2008-05-06</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-05-06</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Practice Point</prism:section>
<prism:startingPage>366</prism:startingPage>
<prism:endingPage>367</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0836">
<title>Is hydrocortisone an effective treatment for septic shock?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0836</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Is hydrocortisone an effective treatment for septic shock?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 368 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0836">doi:10.1038/ncpendmet0836</a>
</p>
<p>Author: Mark S Cooper</p>
]]></content:encoded>
<dc:title>Is hydrocortisone an effective treatment for septic shock?</dc:title>
<dc:creator>Mark S Cooper</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0836</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 368 (2008)</dc:source>
<dc:date>2008-05-06</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-05-06</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Practice Point</prism:section>
<prism:startingPage>368</prism:startingPage>
<prism:endingPage>369</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0841">
<title>Should the upper limit of the normal reference range for TSH be lowered?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0841</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Should the upper limit of the normal reference range for TSH be lowered?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 370 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0841">doi:10.1038/ncpendmet0841</a>
</p>
<p>Author: Martin I Surks</p>
]]></content:encoded>
<dc:title>Should the upper limit of the normal reference range for TSH be lowered?</dc:title>
<dc:creator>Martin I Surks</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0841</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 370 (2008)</dc:source>
<dc:date>2008-05-20</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-05-20</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Practice Point</prism:section>
<prism:startingPage>370</prism:startingPage>
<prism:endingPage>371</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0838">
<title>How does teriparatide compare with alendronate for the treatment of glucocorticoid-induced osteoporosis?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0838</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>How does teriparatide compare with alendronate for the treatment of glucocorticoid-induced osteoporosis?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 372 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0838">doi:10.1038/ncpendmet0838</a>
</p>
<p>Author: Ren&#233; Rizzoli</p>
]]></content:encoded>
<dc:title>How does teriparatide compare with alendronate for the treatment of glucocorticoid-induced osteoporosis?</dc:title>
<dc:creator>Ren&#233; Rizzoli</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0838</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 372 (2008)</dc:source>
<dc:date>2008-05-13</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-05-13</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Practice Point</prism:section>
<prism:startingPage>372</prism:startingPage>
<prism:endingPage>373</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0840">
<title>Does testosterone supplementation improve health and function in elderly men?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0840</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Does testosterone supplementation improve health and function in elderly men?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 374 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0840">doi:10.1038/ncpendmet0840</a>
</p>
<p>Authors: Stephanie T Page, John K Amory
&amp; Alvin M Matsumoto</p>
]]></content:encoded>
<dc:title>Does testosterone supplementation improve health and function in elderly men?</dc:title>
<dc:creator>Stephanie T Page</dc:creator>
<dc:creator>John K Amory</dc:creator>
<dc:creator>Alvin M Matsumoto</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0840</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 374 (2008)</dc:source>
<dc:date>2008-05-20</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-05-20</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Practice Point</prism:section>
<prism:startingPage>374</prism:startingPage>
<prism:endingPage>375</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0845">
<title>Is denosumab a safe and effective treatment for postmenopausal osteoporosis?</title>
<link>http://dx.doi.org/10.1038/ncpendmet0845</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>Is denosumab a safe and effective treatment for postmenopausal osteoporosis?</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 376 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0845">doi:10.1038/ncpendmet0845</a>
</p>
<p>Author: Kathryn E Ackerman</p>
]]></content:encoded>
<dc:title>Is denosumab a safe and effective treatment for postmenopausal osteoporosis?</dc:title>
<dc:creator>Kathryn E Ackerman</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0845</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 376 (2008)</dc:source>
<dc:date>2008-05-27</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-05-27</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Practice Point</prism:section>
<prism:startingPage>376</prism:startingPage>
<prism:endingPage>377</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0839">
<title>The role of energy and nutritional support in the intensive care unit</title>
<link>http://dx.doi.org/10.1038/ncpendmet0839</link>
<description>Malnutrition is common in critically ill, hospitalized patients and so represents a major problem for intensive care. Nutritional support can be beneficial in such cases and may help preserve vital organ and immune function. Energy requirements, route of delivery and potential complications of nutritional support are discussed in this Viewpoint.</description>
<content:encoded><![CDATA[

<p>
<b>The role of energy and nutritional support in the intensive care unit</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 378 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0839">doi:10.1038/ncpendmet0839</a>
</p>
<p>Authors: Mette M Berger
&amp; Ren&#233; L Chiol&#233;ro</p>
]]></content:encoded>
<dc:title>The role of energy and nutritional support in the intensive care unit</dc:title>
<dc:creator>Mette M Berger</dc:creator>
<dc:creator>Ren&#233; L Chiol&#233;ro</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0839</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 378 (2008)</dc:source>
<dc:date>2008-05-13</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-05-13</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Viewpoint</prism:section>
<prism:startingPage>378</prism:startingPage>
<prism:endingPage>379</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0842">
<title>Pharmacologic treatment options for prediabetes</title>
<link>http://dx.doi.org/10.1038/ncpendmet0842</link>
<description>Identification and subsequent treatment of individuals with prediabetes can prevent progression to type 2 diabetes mellitus. Although lifestyle changes are critical in this setting, the question of whether pharmacotherapy should also be used remains unanswered. The authors of this Viewpoint, therefore, discuss potential strategies for pharmacologic intervention.</description>
<content:encoded><![CDATA[

<p>
<b>Pharmacologic treatment options for prediabetes</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 380 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0842">doi:10.1038/ncpendmet0842</a>
</p>
<p>Authors: Willa A Hsueh
&amp; Yehuda Handelsman</p>
]]></content:encoded>
<dc:title>Pharmacologic treatment options for prediabetes</dc:title>
<dc:creator>Willa A Hsueh</dc:creator>
<dc:creator>Yehuda Handelsman</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0842</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 380 (2008)</dc:source>
<dc:date>2008-06-03</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-06-03</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Viewpoint</prism:section>
<prism:startingPage>380</prism:startingPage>
<prism:endingPage>381</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0843">
<title>The prevention of type 2 diabetes</title>
<link>http://dx.doi.org/10.1038/ncpendmet0843</link>
<description>Prediabetic states that involve impairments of insulin secretion and action can be identified. Medical therapy and lifestyle modifications can be used in people with these disorders to delay or prevent the onset of type 2 diabetes. In this Review, the data on development and evaluation of diabetes-prevention strategies are discussed and some recommendations for practice are provided.</description>
<content:encoded><![CDATA[

<p>
<b>The prevention of type 2 diabetes</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 382 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0843">doi:10.1038/ncpendmet0843</a>
</p>
<p>Authors: Jill P Crandall, William C Knowler, Steven E Kahn, David Marrero, Jose C Florez, George A Bray, Steven M Haffner, Mary Hoskin
&amp; David M Nathan</p>
]]></content:encoded>
<dc:title>The prevention of type 2 diabetes</dc:title>
<dc:creator>Jill P Crandall</dc:creator>
<dc:creator>William C Knowler</dc:creator>
<dc:creator>Steven E Kahn</dc:creator>
<dc:creator>David Marrero</dc:creator>
<dc:creator>Jose C Florez</dc:creator>
<dc:creator>George A Bray</dc:creator>
<dc:creator>Steven M Haffner</dc:creator>
<dc:creator>Mary Hoskin</dc:creator>
<dc:creator>David M Nathan</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0843</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 382 (2008)</dc:source>
<dc:date>2008-05-20</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-05-20</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Review</prism:section>
<prism:startingPage>382</prism:startingPage>
<prism:endingPage>393</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0846">
<title>The role of thyroid autoimmunity in fertility and pregnancy</title>
<link>http://dx.doi.org/10.1038/ncpendmet0846</link>
<description>The thyroid gland and thyroid hormones have important roles in fertility and throughout pregnancy. In fertile and infertile women with thyroid disorders, such as hypothyroidism or thyroid autoimmunity, therapy might enable conception, but a host of problems can arise. Poppe et al. present an overview of the interactions between thyroid disorders and spontaneous and assisted pregnancies.</description>
<content:encoded><![CDATA[

<p>
<b>The role of thyroid autoimmunity in fertility and pregnancy</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 394 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0846">doi:10.1038/ncpendmet0846</a>
</p>
<p>Authors: Kris Poppe, Brigitte Velkeniers
&amp; Daniel Glinoer</p>
]]></content:encoded>
<dc:title>The role of thyroid autoimmunity in fertility and pregnancy</dc:title>
<dc:creator>Kris Poppe</dc:creator>
<dc:creator>Brigitte Velkeniers</dc:creator>
<dc:creator>Daniel Glinoer</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0846</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 394 (2008)</dc:source>
<dc:date>2008-05-27</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-05-27</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Review</prism:section>
<prism:startingPage>394</prism:startingPage>
<prism:endingPage>405</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0872">
<title>Endocrine abnormalities in anorexia nervosa</title>
<link>http://dx.doi.org/10.1038/ncpendmet0872</link>
<description>Various endocrine abnormalities arise in anorexia nervosa. Most are related to the body's adaptation to starvation, but some might relate to susceptibility to recurrence, as they persist after recovery. Lawson and Klibanski summarize the main endocrine alterations in girls and women, concentrating particularly on bone loss.</description>
<content:encoded><![CDATA[

<p>
<b>Endocrine abnormalities in anorexia nervosa</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 407 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0872">doi:10.1038/ncpendmet0872</a>
</p>
<p>Authors: Elizabeth A Lawson
&amp; Anne Klibanski</p>
]]></content:encoded>
<dc:title>Endocrine abnormalities in anorexia nervosa</dc:title>
<dc:creator>Elizabeth A Lawson</dc:creator>
<dc:creator>Anne Klibanski</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0872</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 407 (2008)</dc:source>
<dc:date>2008-06-10</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-06-10</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Review</prism:section>
<prism:startingPage>407</prism:startingPage>
<prism:endingPage>414</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0844">
<title>Treatment of male infertility secondary to morbid obesity</title>
<link>http://dx.doi.org/10.1038/ncpendmet0844</link>
<description>Obesity can be a cause of secondary hypogonadism. This article describes a male patient with infertility in the setting of obesity, who was successfully treated with the aromatase inhibitor anastrozole. The authors illustrate the connections between adiposity, aromatase expression, testosterone and estradiol levels, and the suppression of gonadotropin release and spermatogenesis.</description>
<content:encoded><![CDATA[

<p>
<b>Treatment of male infertility secondary to morbid obesity</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 415 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0844">doi:10.1038/ncpendmet0844</a>
</p>
<p>Authors: Mara Y Roth, John K Amory
&amp; Stephanie T Page</p>
]]></content:encoded>
<dc:title>Treatment of male infertility secondary to morbid obesity</dc:title>
<dc:creator>Mara Y Roth</dc:creator>
<dc:creator>John K Amory</dc:creator>
<dc:creator>Stephanie T Page</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0844</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 415 (2008)</dc:source>
<dc:date>2008-06-03</dc:date>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:publicationDate>2008-06-03</prism:publicationDate>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Case Study</prism:section>
<prism:startingPage>415</prism:startingPage>
<prism:endingPage>419</prism:endingPage>
</item>
<item rdf:about="http://dx.doi.org/10.1038/ncpendmet0888">
<title>A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet</title>
<link>http://dx.doi.org/10.1038/ncpendmet0888</link>
<description/>
<content:encoded><![CDATA[

<p>
<b>A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet</b>
</p>
<p>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 420 (2008). <a href="http://dx.doi.org/10.1038/ncpendmet0888">doi:10.1038/ncpendmet0888</a>
</p>
<p>Authors: Alberto Falchetti, Antonio Cilotti, Luca Vagelli, Laura Masi, Antonietta Amedei, Federica Cioppi, Francesco Tonelli
&amp; Maria Luisa Brandi</p>
]]></content:encoded>
<dc:title>A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet</dc:title>
<dc:creator>Alberto Falchetti</dc:creator>
<dc:creator>Antonio Cilotti</dc:creator>
<dc:creator>Luca Vagelli</dc:creator>
<dc:creator>Laura Masi</dc:creator>
<dc:creator>Antonietta Amedei</dc:creator>
<dc:creator>Federica Cioppi</dc:creator>
<dc:creator>Francesco Tonelli</dc:creator>
<dc:creator>Maria Luisa Brandi</dc:creator>
<dc:identifier>doi:10.1038/ncpendmet0888</dc:identifier>
<dc:source>Nature Clinical Practice Endocrinology &amp; Metabolism 4, 420 (2008)</dc:source>
<prism:publicationName>Nature Clinical Practice Endocrinology &amp; Metabolism</prism:publicationName>
<prism:volume>4</prism:volume>
<prism:number>7</prism:number>
<prism:section>Corrigendum</prism:section>
<prism:startingPage>420</prism:startingPage>
<prism:endingPage>420</prism:endingPage>
</item>
</rdf:RDF>
